Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alpha Cognition Inc. (ACOG)

Alpha Cognition appoints Bethany Sensenig to board as director

Neutral Impact 2 of 5 leadership Written later

Alpha Cognition Inc. appointed Bethany Sensenig as a director on April 15, 2026. She previously served as CFO and Head of Operations at Radius Health, Inc. and holds a board seat at Supernus Pharmaceuticals and KalVista Pharmaceuticals; the filing describes no compensation beyond the company's standard non-employee director policy and grants.

Key points

  • Board appointment of Bethany Sensenig effective April 15, 2026
  • Initial grant of 5,489 restricted stock units and 6,991 stock options at an exercise price of $6.65 per share
  • Grants vest one year after the date of grant
  • Prior roles include CFO at Radius Health (May 2024 to April 2026) and CFO and Interim CEO at 9 Meters Biopharma

The filing

CompanyAlpha Cognition Inc. (ACOG)
Form8-K, current report
Filed with the SECApr 20, 2026, 5:00 PM ET
Accession number0001213900-26-045668

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.